That gap, between knowing what good looks like and being able to act while the market is still moving, is what I wanted to put to someone who has lived it. Lou has spent three decades in commercialization and has since sat on the other side of the table, advising the teams making these calls. Not a vendor with a platform to sell. An operator who has watched launches drift in real time and can tell you where and why. My thanks to him for a genuinely candid hour, and for being

From Ivy Tree Advisors Pharma's commercial and customer experience landscape is undergoing its most significant transformation in a generation. "Better CX" in pharma means less friction, more trustworthy information, and faster time to therapy not better marketing. The imperative has shifted from "should we use AI?" to "are we using it to solve the right problems, in the right workflows, for the right people?" EXECUTIVE SUMMARY 1. AI driven Next Best Action is delivering me

We're probably at the peak of the AI hype cycle. Your teams have moved beyond experimenting with ChatGPT—they're now integrating AI into...

The AI-powered drug discovery platform market is set to reach $1.29 billion in 2025, and surge to $8.27 billion by 2035—a rapid ~20%...